Genmab A/S (NASDAQ:GMAB) Shares Sold by Sanctuary Advisors LLC

Sanctuary Advisors LLC cut its holdings in shares of Genmab A/S (NASDAQ:GMAB) by 39.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 32,800 shares of the company’s stock after selling 21,093 shares during the quarter. Sanctuary Advisors LLC’s holdings in Genmab A/S were worth $800,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC increased its stake in shares of Genmab A/S by 123.0% during the second quarter. Allspring Global Investments Holdings LLC now owns 3,240 shares of the company’s stock worth $81,000 after buying an additional 1,787 shares during the period. Blue Trust Inc. increased its position in shares of Genmab A/S by 892.0% in the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock valued at $108,000 after purchasing an additional 3,880 shares during the last quarter. Headlands Technologies LLC raised its holdings in shares of Genmab A/S by 1,702.8% in the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock valued at $129,000 after purchasing an additional 4,853 shares in the last quarter. Benjamin F. Edwards & Company Inc. lifted its position in shares of Genmab A/S by 7.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock worth $182,000 after purchasing an additional 478 shares during the last quarter. Finally, Mount Yale Investment Advisors LLC acquired a new position in shares of Genmab A/S during the third quarter worth $192,000. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Stock Performance

Shares of Genmab A/S stock opened at $20.76 on Tuesday. The company has a market capitalization of $13.74 billion, a P/E ratio of 20.16, a PEG ratio of 0.67 and a beta of 0.96. Genmab A/S has a 1 year low of $19.85 and a 1 year high of $32.88. The company’s fifty day moving average is $21.80 and its two-hundred day moving average is $24.75.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The company had revenue of $816.10 million for the quarter, compared to analysts’ expectations of $838.20 million. During the same period in the prior year, the business earned $0.47 EPS. As a group, equities analysts expect that Genmab A/S will post 1.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

GMAB has been the subject of a number of recent analyst reports. Redburn Atlantic started coverage on Genmab A/S in a report on Tuesday, October 8th. They set a “buy” rating for the company. Truist Financial lowered their price target on Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a report on Monday, September 9th. BMO Capital Markets reissued an “outperform” rating and set a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a report on Wednesday, October 16th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $31.00 price target on shares of Genmab A/S in a research note on Wednesday, September 11th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Genmab A/S has a consensus rating of “Moderate Buy” and a consensus price target of $45.20.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.